Company ProfilePremiumNov 11, 2026

Alliqua BioMedical, Inc.

Company Profile Analysis

Book Demo Register Your Interest

Alliqua BioMedical, Inc. - Healthcare showcase

Year Founded & Workforce

2014

60 Employees

Industry

Healthcare

Services

Human Biologics

Alliqua BioMedical, Inc. Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Alliqua BioMedical, Inc. Overview

Company Headquarters: Pennsylvania, US

Founded: 2014

Workforce: 60+

Company Working: Alliqua BioMedical, Inc. (Alliqua) is into the development and manufacturing of electron-beam cross-linked sheet gels for customers that include manufacturers of medical devices, cosmeceuticals, and other commercial product applications. The company specializes in wound management, contract manufacturing, biopharmaceuticals, and hydrogels. Its hydrogel platform technology assists in manufacturing electron-beam cross-linked sheet gels with or without active ingredients. Prescription or over-the-counter medications, ingredients for wound healing and skin care, or other materials, can be effectively delivered using this platform.

Strategy

Alliqua focuses on strategic alliances and acquisitions to expand in the market. The company also focuses on meeting specific needs of customers, maintain tight tolerances, ensure prompt delivery, and provide superior customer service.

Company Snapshot

$12.2M

Revenue

Employees

2014

Founded

Pennsylvania, US

Headquarters

SWOT Analysis

Strengths

Strong brand recognition Track record of innovation

Weaknesses

Material breach of supply agreements can tarnish company’s image

Opportunities

Launching more products to its product portfolio

Threats

Strict government regulations

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

Date	Approach	Development
October 2018	Merger	Alliqua and Adynxx, Inc. announced a merger agreement for forming a NASDAQ listed clinical-stage pharmaceutical company with a major focus on pain and inflammation.
January 2018	Acquisition	Alliqua announced the definitive asset purchase agreement with Celularity, Inc. under which Celularity will acquire all of the property, assets, and rights relating to Alliqua’s advanced biologic wound care business.
February 2015	Acquisition	Alliqua acquired Celleration, Inc. to expand its proprietary product portfolio and salesforce in the advanced wound care market.
October 2014	Licensing Agreement	Alliqua announced the expansion to its exclusive licensing agreement with Celgene Cellular therapeutics. This stretches the use of Biovance in podiatric and orthopedic applications as well.
May 2014	Acquisition	Alliqua acquired Choice Therapeutics to add new wound care products to its world-class technology platform.
April 2014	Product Launch	Alliqua launched Biovance, a human amniotic membrane allograft product licensed from Celgene.

Product Offering

Alliqua BioMedical, Inc.
- Human Biologics

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

By Business Segment: Sales rose from USD 12.2 Mn in 2015 to USD 19.6 Mn in 2017.

Alliqua BioMedical, Inc. — By Business Segment
Series (USD Mn)	2015	2016	2017
Sales	12.2	18.2	19.6
R&D Expenses	0.7	0.9	0.1

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.

Get Contacts →

About the Author

Wantstats Research Team

Wantstats' research desk profiles Alliqua BioMedical, Inc. as part of our ongoing coverage of the Healthcare sector, drawing on public company data, filings, and market intelligence.

Powering the world's best teams.
From next-gen startups to established enterprises.

See our work in action

Start your data driven journey with us!

Book a Demo Now

What our clients say

Trusted by forward-thinking businesses
for data-driven intelligence

Noah Malgeri

Co-Founder, Mojave Rail Fabrication Limited

This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job.

Michael Robert

Manager, JavolVision

Thanks, I am so happy that we worked together. Maybe we still can work together in the future.

Joseph Aguayo

Sales Operations & Pricing Manager, Intel

Thanks. It's been a pleasure working with you, please use me as reference with any other Intel employees.

Bong Lau

Sales Leader, Bamberg

We bought your "2025 report" in 2020. Everything is fine and very good.

Peter Groot Koerkamp

Account and Business Manager, EFS-Holland BV

Thanks for sending the report it gives us a good global view of the Betaïne market.

Younghwan Choi

Senior Retail Manager, LG Chem

We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.

Mark Irwin

Management Consultant, Level 21

I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.

Rob Kooiker

Group Product Manager HVAC & Fire Protection GMA, Rockwool

I have been reading the first document or the study, the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!

Jason Lee

R&D Director, Seojin

Thanks for your great support. Appreciate it. Well received report. It helps us to understand market well. We're planning other area of survey in the future, let's keep in touch.

Akif Moroglu

Strategy & Business Development Director, Dogan Holding

We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.